Economics of unfractionated heparin

Beyond acquisition cost

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite numerous clinical trials demonstrating advantages of new anticoagulants, unfractionated heparin (UFH) is still used by a number of clinicians in the United States. The reason for this continued use of UFH is not superior efficacy, improved safety, or convenience, but low acquisition cost. However, several other costs associated with the use of UFH are often not considered. Appropriate economic analysis, which considers both cost and outcomes, has not demonstrated support for continued use of UFH. Its continued use based simply on lower cost is not justified by the literature.

Original languageEnglish (US)
JournalPharmacotherapy
Volume24
Issue number8 II
DOIs
StatePublished - Aug 1 2004

Fingerprint

Heparin
Economics
Costs and Cost Analysis
Anticoagulants
Clinical Trials
Safety

Keywords

  • Bleeding episodes
  • Economic analysis
  • Heparin-induced thrombocytopenia
  • Low-molecular-weight heparins
  • Unfractionated heparin
  • Venous thromboembolism

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Economics of unfractionated heparin : Beyond acquisition cost. / Dobesh, Paul P.

In: Pharmacotherapy, Vol. 24, No. 8 II, 01.08.2004.

Research output: Contribution to journalArticle

@article{36c8cfc5bdce4d57b42244518a11a5a0,
title = "Economics of unfractionated heparin: Beyond acquisition cost",
abstract = "Despite numerous clinical trials demonstrating advantages of new anticoagulants, unfractionated heparin (UFH) is still used by a number of clinicians in the United States. The reason for this continued use of UFH is not superior efficacy, improved safety, or convenience, but low acquisition cost. However, several other costs associated with the use of UFH are often not considered. Appropriate economic analysis, which considers both cost and outcomes, has not demonstrated support for continued use of UFH. Its continued use based simply on lower cost is not justified by the literature.",
keywords = "Bleeding episodes, Economic analysis, Heparin-induced thrombocytopenia, Low-molecular-weight heparins, Unfractionated heparin, Venous thromboembolism",
author = "Dobesh, {Paul P}",
year = "2004",
month = "8",
day = "1",
doi = "10.1592/phco.24.12.161S.36108",
language = "English (US)",
volume = "24",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8 II",

}

TY - JOUR

T1 - Economics of unfractionated heparin

T2 - Beyond acquisition cost

AU - Dobesh, Paul P

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Despite numerous clinical trials demonstrating advantages of new anticoagulants, unfractionated heparin (UFH) is still used by a number of clinicians in the United States. The reason for this continued use of UFH is not superior efficacy, improved safety, or convenience, but low acquisition cost. However, several other costs associated with the use of UFH are often not considered. Appropriate economic analysis, which considers both cost and outcomes, has not demonstrated support for continued use of UFH. Its continued use based simply on lower cost is not justified by the literature.

AB - Despite numerous clinical trials demonstrating advantages of new anticoagulants, unfractionated heparin (UFH) is still used by a number of clinicians in the United States. The reason for this continued use of UFH is not superior efficacy, improved safety, or convenience, but low acquisition cost. However, several other costs associated with the use of UFH are often not considered. Appropriate economic analysis, which considers both cost and outcomes, has not demonstrated support for continued use of UFH. Its continued use based simply on lower cost is not justified by the literature.

KW - Bleeding episodes

KW - Economic analysis

KW - Heparin-induced thrombocytopenia

KW - Low-molecular-weight heparins

KW - Unfractionated heparin

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=3543110740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543110740&partnerID=8YFLogxK

U2 - 10.1592/phco.24.12.161S.36108

DO - 10.1592/phco.24.12.161S.36108

M3 - Article

VL - 24

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8 II

ER -